GLYR1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the GLYR1 gene has been disrupted in the Raji B lymphocyte cell line. This loss-of-function model enables investigation of GLYR1-dependent processes in a human Burkitt lymphoma background. The polyclonal knockout format preserves cellular heterogeneity while eliminating functional GLYR1 protein, providing a robust system for studying the scaffold protein??s role in chromatin remodeling and Wnt pathway-mediated transcriptional regulation.
The Raji cell line is an Epstein-Barr virus (EBV)-positive lymphoblastoid cell line originally derived from a Burkitt lymphoma patient, widely employed as a model for B lymphocyte biology and B cell malignancies. Raji cells express hallmark B cell surface markers and retain key signaling pathways relevant to lymphomagenesis, making them a suitable host for dissecting the molecular mechanisms underlying lymphomagenesis. The knockout of GLYR1 in this context allows direct interrogation of its contribution to the transformed phenotype and epigenetic dysregulation characteristic of aggressive B cell lymphomas.
GLYR1 functions as a nuclear scaffold bridging SETD2 histone methyltransferase with beta-catenin (CTNNB1), facilitating H3K36 trimethylation and transcriptional activation of Wnt target genes. During canonical Wnt signaling, Wnt ligands engage Frizzled receptors, stabilizing beta-catenin, which translocates to the nucleus and associates with TCF/LEF transcription factors. GLYR1 is recruited to Wnt-responsive promoters via beta-catenin, where it coordinates SETD2-mediated H3K36me3 deposition, promoting RNA polymerase II processivity. It also interacts with MLL complex components, emphasizing its role in integrating chromatin remodeling and transcription.
In B cell lymphomas, aberrant activation of Wnt/beta-catenin signaling has been implicated in tumor progression and maintenance. GLYR1??s capacity to couple beta-catenin to the H3K36 methyltransferase SETD2 positions it as a crucial mediator of oncogenic transcriptional programs. The GLYR1 Knockout Raji Polyclonal Cells provide a valuable tool to dissect how loss of this scaffold disrupts Wnt target gene expression and histone modification dynamics in lymphoma cells. Researchers can use this model to explore the dependence of lymphoma cells on GLYR1-mediated epigenetic regulation, evaluate changes in proliferation and apoptosis, and assess sensitivity to targeted therapies.
Typical applications include functional validation of the GLYR1?CSETD2?CCTNNB1 axis through chromatin immunoprecipitation (ChIP-qPCR) for H3K36me3 at Wnt target loci, quantitative RT-qPCR and western blotting to monitor Wnt pathway activity, and Wnt luciferase reporter assays to measure transcriptional output. Proliferation assays and flow cytometry allow assessment of cell cycle changes and apoptosis upon GLYR1 loss. Furthermore, these polyclonal knockout cells are suitable for drug target validation and synthetic lethality screens in B cell lymphoma. For additional information or customized cell engineering services, please contact Ascent Research.
